---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-062296"
form_type: "8-K"
ticker: "REPL"
cik: "0001737953"
company_name: "Replimune Group, Inc."
filed_at: "2024-05-16T23:59:59+00:00"
generated_at: "2026-06-01T21:31:48.733994+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Replimune posts Q4 net loss $55.1M; RP1 melanoma BLA on track for 2H 2024

## Summary
- Net loss of $55.1M for Q4 FY2024; full-year net loss $215.8M vs $174.3M prior year.
- Cash, equivalents & investments $420.7M; cash runway projected into 2H 2026.
- Primary analysis of IGNYTE trial (RP1 + nivolumab) in anti-PD1 failed melanoma expected Q2 2024.
- BLA submission for RP1 in anti-PD1 failed melanoma planned for 2H 2024 after positive FDA CMC meeting.
- First patient enrollment in Phase 3 IGNYTE-3 confirmatory trial expected 2H 2024.

## SEC filing metadata
- accession: 0001104659-24-062296
- form_type: 8-K
- ticker: REPL
- cik: 0001737953
- company_name: Replimune Group, Inc.
- filed_at: 2024-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737953/000110465924062296/0001104659-24-062296-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737953/000110465924062296/tm2413978d4_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-062296
- JSON: https://secwatch.observer/filing/0001104659-24-062296.json
- Plain text: https://secwatch.observer/filing/0001104659-24-062296.txt

## Key facts
- Earnings Releases
  Replimune Group, Inc. reported financial results for the fourth quarter and year ended March 31, 2024.
  - Period: the fourth quarter and year ended March 31, 2024
  - Result: reported results
  source text: Replimune Group, Inc. (the "Company") issued a news release announcing its financial results for the fourth quarter and year ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737953/000110465924062296/0001104659-24-062296-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.